U.S. Government will support the scale-up of INOVIO's proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO's COVID-19 vaccine

The DoD contract, from the JPEO-CRBND-EB through funding provided by the Defense Health Program, builds upon two separate prior $5 million grants from the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI), to accelerate the testing of CELLECTRA® 3PSP. Initial development of this next generation CELLECTRA® 3PSP smart device began in 2019 with $8.1 million in funding from the medical arm of the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium.

Sauce: https://www.prnewswire.com/news-releases/inovio-receives-71-million-contract-from-us-department-of-defense-to-scale-up-manufacture-of-cellectra-3psp-smart-device-and-procurement-of-cellectra-2000-for-covid-19-dna-vaccine-301081866.html

==Tolerability of intramuscular and intradermal delivery by CELLECTRA® adaptive constant current electroporation device in healthy volunteers

==

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906411/